FutureLife Partners with Alife Health for AI-Driven Fertility Care Across Europe
In a groundbreaking announcement, FutureLife Group has partnered with Alife Health to implement an innovative AI-driven platform aimed at transforming fertility care across Europe. As the first major pan-European fertility network, FutureLife will introduce this comprehensive system in its clinics, which span 16 countries, leading the charge towards data-driven fertility treatments.
The centerpiece of this collaboration is Alife Health's state-of-the-art Embryo Predict™ tool, which has received the requisite CE mark certification under the European Union Medical Device Regulation. This AI tool enhances the clinical decision-making process by supporting clinicians in the assessment of embros for transfer decisions. This not only enhances the chances of successful pregnancies but also provides patients with personalized insights.
The new platform integrates various AI-driven tools, offering a seamless experience throughout the in-vitro fertilization (IVF) process. From pre-treatment planning to the selection of embryos for transfer, the platform aims to improve consistency and transparency. With tools like the Success Predictor—a non-medical device that forecasts treatment outcomes—and the Egg Retrieval Report that keeps patients informed about their changing success probabilities, the goal is to create a more supportive and informative experience for those undergoing fertility treatments.
"Fertility care must continuously evolve to reflect the best available science," says Francisco Lobbosco, CEO of FutureLife Group. This ambitious step signifies the organization's commitment to raising the standards of care for the many families that rely on these services. By embedding the latest AI technology into their clinical workflows, FutureLife is setting a new benchmark for what patients can expect.
This partnership follows a successful pilot program involving multiple clinics within the network, which yielded promising results. According to Amy Barrie, FutureLife's Chief Scientific Officer, embracing this technology offers a more objective, data-backed foundation for clinical decisions, ultimately enhancing the overall performance of their laboratories.
The significance of this partnership transcends mere technical integration. It indicates a significant shift in how fertility treatment is administered across Europe. "When a leading fertility network makes an institutional commitment to AI innovations, it sends a clear signal that this technology is beginning to move from experimental phases to standard practice," notes Melissa Teran, CEO and Co-Founder of Alife Health.
FutureLife Group operates around 60 clinics and processes over 77,000 IVF cycles annually, employing a workforce of over 2,400 specialists. This partnership with Alife Health represents not only a commitment to better clinical outcomes but also marks a strategic expansion of FutureLife's influence across the European healthcare landscape, showcasing their commitment to both growth and ethical practices in fertility treatments.
Founded in 1991, FutureLife has already helped bring over 185,000 babies into the world, underpinning a belief in the fundamental right of individuals to build their families. As they leverage these technological advancements, they continue to focus on ethical standards and the integration of scientifically validated approaches to fertility treatments.
From embryo selection to providing outcome projections and insights into the IVF journey, this collaboration between FutureLife and Alife Health is poised to redefine patient experiences and expectations in the landscape of reproductive healthcare, ultimately fostering hope for many looking to conceive.
The centerpiece of this collaboration is Alife Health's state-of-the-art Embryo Predict™ tool, which has received the requisite CE mark certification under the European Union Medical Device Regulation. This AI tool enhances the clinical decision-making process by supporting clinicians in the assessment of embros for transfer decisions. This not only enhances the chances of successful pregnancies but also provides patients with personalized insights.
The new platform integrates various AI-driven tools, offering a seamless experience throughout the in-vitro fertilization (IVF) process. From pre-treatment planning to the selection of embryos for transfer, the platform aims to improve consistency and transparency. With tools like the Success Predictor—a non-medical device that forecasts treatment outcomes—and the Egg Retrieval Report that keeps patients informed about their changing success probabilities, the goal is to create a more supportive and informative experience for those undergoing fertility treatments.
"Fertility care must continuously evolve to reflect the best available science," says Francisco Lobbosco, CEO of FutureLife Group. This ambitious step signifies the organization's commitment to raising the standards of care for the many families that rely on these services. By embedding the latest AI technology into their clinical workflows, FutureLife is setting a new benchmark for what patients can expect.
This partnership follows a successful pilot program involving multiple clinics within the network, which yielded promising results. According to Amy Barrie, FutureLife's Chief Scientific Officer, embracing this technology offers a more objective, data-backed foundation for clinical decisions, ultimately enhancing the overall performance of their laboratories.
The significance of this partnership transcends mere technical integration. It indicates a significant shift in how fertility treatment is administered across Europe. "When a leading fertility network makes an institutional commitment to AI innovations, it sends a clear signal that this technology is beginning to move from experimental phases to standard practice," notes Melissa Teran, CEO and Co-Founder of Alife Health.
FutureLife Group operates around 60 clinics and processes over 77,000 IVF cycles annually, employing a workforce of over 2,400 specialists. This partnership with Alife Health represents not only a commitment to better clinical outcomes but also marks a strategic expansion of FutureLife's influence across the European healthcare landscape, showcasing their commitment to both growth and ethical practices in fertility treatments.
Founded in 1991, FutureLife has already helped bring over 185,000 babies into the world, underpinning a belief in the fundamental right of individuals to build their families. As they leverage these technological advancements, they continue to focus on ethical standards and the integration of scientifically validated approaches to fertility treatments.
From embryo selection to providing outcome projections and insights into the IVF journey, this collaboration between FutureLife and Alife Health is poised to redefine patient experiences and expectations in the landscape of reproductive healthcare, ultimately fostering hope for many looking to conceive.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.